DRUGTARGETREVIEW.COM

Domain Rank: 88,096

Last Updated: June 17, 2024

DRUGTARGETREVIEW.COM Summary

drugtargetreview.com has 2 NS records, 2 A records, 2 AAAA records, 1 MX records, and 3 TXT records. Name servers for drugtargetreview.com are ram.ns.cloudflare.com, erin.ns.cloudflare.com. A records for drugtargetreview.com are 172.66.40.185, 172.66.43.71. AAAA records for drugtargetreview.com are 2606:4700:3108:0:0:0:ac42:28b9, 2606:4700:3108:0:0:0:ac42:2b47. MX records that process @drugtargetreview.com email are drugtargetreview-com.mail.protection.outlook.com. We have observed drugtargetreview.com to have 9 subdomains. A subdomain count of 9 is considered a small digital footprint. Technology that may be in use at drugtargetreview.com includes logmein. The domain's primary website is hosted on a cloudflare web server at 172.66.40.185 in United States. The website's description is: "the leading drug discovery website" The website's description is: "stay at the forefront of drug discovery and therapeutic development with drug target review. dive into the latest research, industry analysis and technological advancements. connect with world-renowned scientists and explore peer-reviewed articles, webinars, and more." As of June 17, 2024, drugtargetreview.com does not have any threat intelligence reports of concern.

Search DigitalStakeout ASI to find another asset.

DRUGTARGETREVIEW.COM DNS Records

TXT Records

drugtargetreview.com. 300 IN TXT "v=spf1 include:spf.protection.outlook.com +ip4:185.41.10.197 +a +mx +ip4:46.29.88.178 +include:msgfocus.com ~all"

drugtargetreview.com. 300 IN TXT "MS=ms79113210"

drugtargetreview.com. 300 IN TXT "logmein-verification-code=4e0c1389-a998-4c26-a5f2-93476fa51474"

Search DigitalStakeout ASI to find another asset.

DRUGTARGETREVIEW.COM Subdomains

drugtargetreview.com has 9 subdomains in our inventory.

Hostname IP Address
drugtargetreview.com 172.66.40.185
emails.drugtargetreview.com 37.221.223.30
mail.drugtargetreview.com 172.66.43.71
www.drugtargetreview.com 172.66.43.71
e-mail.drugtargetreview.com 37.221.223.30
webinars.drugtargetreview.com 37.221.223.30
cpanel.drugtargetreview.com 172.66.40.185
webmail.drugtargetreview.com 172.66.43.71
webdisk.drugtargetreview.com 172.66.40.185

Search DigitalStakeout ASI to find another asset.

DRUGTARGETREVIEW.COM Website

Web Server

cloudflare

IP Address

172.66.40.185

Country

United States

Meta Tags

og:locale: en_gb

og:type: website

og:title: drug target review

og:description: the leading drug discovery website

og:url: https://www.drugtargetreview.com

og:site_name: drug target review

og:locale: en_gb

og:type: website

og:title: home

og:description: stay at the forefront of drug discovery and therapeutic development with drug target review. dive into the latest research, industry analysis and technological advancements. connect with world-renowned scientists and explore peer-reviewed articles, webinars, and more.

og:url: https://www.drugtargetreview.com/

og:site_name: drug target review

article:publisher: https://www.facebook.com/drugtargetreview

article:modified_time: 2023-09-28t10:21:30+00:00

Search DigitalStakeout ASI to find another asset.

DRUGTARGETREVIEW.COM Certificate Trust

Certificate Trust Log

{"data":{"cert_index":875397393,"cert_link":"https:\/\/ct.googleapis.com\/logs\/eu1\/xenon2024\/ct\/v1\/get-entries?start=875397393&end=875397393","leaf_cert":{"all_domains":["*.drugtargetreview.com","drugtargetreview.com"],"extensions":{"authorityInfoAccess":"CA Issuers - URI:http:\/\/pki.goog\/repo\/certs\/gts2a1.der\nOCSP - URI:http:\/\/ocsp.pki.goog\/s\/gts2a1\/J7kDDWGEzk0\n","authorityKeyIdentifier":"keyid:93:18:63:91:17:76:9A:5A:E6:3B:7F:2E:33:83:84:86:6B:1E:D4:F9\n","basicConstraints":"CA:FALSE","certificatePolicies":"Policy: 1.3.6.1.4.1.11129.2.5.3.1\nPolicy: 2.23.140.1.2.1","crlDistributionPoints":"Full Name:\n URI:http:\/\/crls.pki.goog\/gts2a1\/kCoWddyI7tY.crl","ctlPoisonByte":true,"extendedKeyUsage":"TLS Web server authentication","extra":["1.3.6.1.4.1.11129.2.1.22"],"keyUsage":"Digital Signature","subjectAltName":"DNS:*.drugtargetreview.com, DNS:drugtargetreview.com","subjectKeyIdentifier":"2B:4D:2F:47:19:29:D0:B1:C6:D3:C5:DD:12:AC:FF:F3:82:B5:C8:BC"},"fingerprint":"48:1A:50:3D:EB:E6:96:E9:AF:F8:0E:42:A4:9D:4A:28:1B:35:05:30","issuer":{"C":"US","CN":"GTS CA 2A1","L":null,"O":"Google Trust Services LLC","OU":null,"ST":null,"aggregated":"\/C=US\/CN=GTS CA 2A1\/O=Google Trust Services LLC","emailAddress":null},"not_after":1708744319,"not_before":1704856320,"serial_number":"45F391BCEC46DD1C137A2732EDC27BD2","signature_algorithm":"sha256, ecdsa","subject":{"C":null,"CN":"drugtargetreview.com","L":null,"O":null,"OU":null,"ST":null,"aggregated":"\/CN=drugtargetreview.com","emailAddress":null}},"seen":1704860152.850727,"source":{"name":"Google 'Xenon2024' log","url":"https:\/\/ct.googleapis.com\/logs\/eu1\/xenon2024\/"},"update_type":"PrecertLogEntry"},"message_type":"certificate_update"}

Search DigitalStakeout ASI to find another asset.